Print

Stentys to Present One-Year Interim Results From APPOSITION III Study at TCT Conference  
10/15/2012 10:03:30 AM

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced today that one-year interim results from the APPOSITION III study will be presented during the Transcatheter Cardiovascular Therapeutics (TCT) conference, October 22-26, 2012 in Miami. Prof. Harald Mudra, M.D., Ph.D., of Klinikum Neuperlach (Munich, Germany) will present the results during the morning spotlight session “Primary PCI for STEMI: Drugs, Devices, and Technique Controversies” on Thursday, October 25, 2012 at 9:58 a.m.
//-->